So how does it work?
The Johnson and Johnson (J&J) jab uses “virus vector” technology similar to that of the AstraZeneca-Oxford Vaccine – exploit a virus to act like a Trojan horse which slips part of the genetic model of the coronavirus into a cell of the body.
The cell machinery will then produce a harmless piece of the virus that causes COVID-19. This lump is known as a spike protein.
The body’s immune system recognizes that it is not part of it and therefore begins to produce antibodies and activate other immune cells to fight off what it thinks is an infection.
The vaccine, developed by the pharmaceutical arm of the Janssen Company, was found to be 67% effective overall in preventing moderate to severe infections. COVID-19[feminine[feminine, with some studies suggesting that it also offers comprehensive protection against hospitalization and death.
How is it used?
J&J vaccine only needs to be stored at refrigerator temperature, which greatly facilitates storage, distribution and handling.
The fact that it only requires one dose, unlike others that require two to several weeks apart, could help speed up the rollout of the vaccination.
How many doses has the UK ordered?
The Vaccine Taskforce initially ordered 30 million doses, based on anticipated clinical needs at the time, but with the successful rollout of the vaccine in the UK, the government decided to change its original order to 20 million. .
The first deliveries are expected to arrive in the country later this year now the jab has been cleared by the Medicines and Health Products Regulatory Agency (MHRA).
However, it has been reported that J&J expects to miss its delivery targets for the European Union this quarter.
What other vaccines does the UK have?
So far the Modern, Pfizer-BioNTech and the Oxford-AstraZeneca vaccines are being rolled out across the UK.
The approval of the J&J vaccine comes as it is believed that the most vulnerable groups of people, including the elderly, will be offered a booster vaccine before next winter.
The UK has also ordered 60 million doses of Novavax vaccine pending approval.
What about these blood clot problems?
The MHRA is believed to have refrained from promptly approving the vaccine after concerns have been raised in the US about a link to extremely rare blood clots.
The clots are similar to those seen in a very small proportion of people who have received the Oxford-AstraZeneca jab.
And in April, use of the vaccine was suspended in the United States as the United States Centers for Disease Control and Prevention (CDC) investigated eight “serious” cases of rare blood clots associated with platelet hypoplasia. blood, among the seven million people who had been vaccinated with it.
One person died.
However, the vaccine rollout resumed after a week – after concerns were allayed.
The European Medicines Agency also recommended that a warning about unusual blood clots with a low platelet count should be added to the product information of the vaccine, but said the overall benefits of the vaccine “outweigh” the risk of side effects ”.
The Joint Committee on Vaccination and Immunization (JCVI) will submit updated advice for the Janssen vaccine before doses are available.
Listen and follow the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker